They found that LINC01871 was positively associated with cancer immunity (expression levels of CD8+ T cell, cytolytic immune activity, and PD-L1), which suggests that LINC01871 is a useful biomarker for assessing immunotherapy response. The gene discussed is CD8A; the disease is cancer.